RECOMBINANT INTERFERON ENHANCES MONOCLONAL-ANTIBODY - TARGETING OF CARCINOMA LESIONS INVIVO
RECOMBINANT INTERFERON ENHANCES MONOCLONAL-ANTIBODY - TARGETING OF CARCINOMA LESIONS INVIVO
复制标题
DOI：
10.1126/science.3580039
复制
发表时间：
1987-02-20
期刊：
影响因子：
56.9
通讯作者：
SCHLOM, J
中科院分区：
文献类型：
--
作者：
GREINER, JW;GUADAGNI, F;SCHLOM, J
由单克隆抗体的结合定义的肿瘤相关抗原表达的异质性是大多数（如果不是全部）人类癌细胞群的共同特征。群体内的抗原阴性细胞由于无法结合适当的抗体而可以逃避检测和治疗。因此，在设计单克隆抗体治疗癌症方案时，抗原异质性的程度是一个重要的考虑因素。抵消抗原异质性影响的一种方法是使用重组人白细胞干扰素(Hu-IFN-αA)的克隆A。体内Hu-IFN-αA的施用有效地增加了人结肠异种移植物原位表达的肿瘤抗原的量并增强了放射性标记的单克隆抗体对肿瘤位点的定位。因此，Hu-IFN-αA和单克隆抗体的同时施用可有效克服癌细胞群的抗原异质性并增强单克隆抗体在癌病变的检测和治疗中的功效。
Heterogeneity in the expression of tumor-associated antigens, as defined by the binding of monoclonal antibodies, is a characteristic common to most, if not all, human carcinoma cell populations. Antigen-negative cells within the population can escape detection and therapy by their failure to bind the appropriate antibody. Therefore, the extent of antigenic heterogeneity is an important consideration when designating protocols for the management of cancer by administration of monoclonal antibodies. One approach to counteracting the effect of antigenic heterogeneity is the use of clone A of recombinant human leukocyte interferon (Hu-IFN-.alpha.A). Administration of Hu-IFN-.alpha.A in vivo effectively increased the amount of tumor antigen expressed by a human colon xenograft in situ and augmented the localization of a radiolabeled monoclonal antibody to the tumor site. Concomitant administration of Hu-IFN-.alpha.A and monoclonal antibody may thus be effective in overcoming the antigenic heterogeneity of carcinoma cell populations and in enhancing the efficacy of monoclonal antibodies in the detection and treatment of carcinoma lesions.